Literature DB >> 28450936

The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis.

Su-Jin Shin1, Kwang-Ho Lee2, Kyung-Sook Chung1, Se-Yun Cheon1, Hyo-Jin An1.   

Abstract

Benign prostatic hyperplasia (BPH) is a pathological condition that affects the majority of men above the age of 50 years. Pharmacological agents are typically used to treat BPH; however, there are currently no pharmacological agents that are able to completely cure BPH without causing adverse side effects. As a result of these side effects, there is a great interest in developing effective herbal medicines that are able to inhibit the progression of BPH and are safe for long-term use. Ga-Gam-Nai-Go-Hyan (GGN) is a traditional Korean herbal medicine that has been widely used to treat BPH; however, no biological studies have been performed to elucidate the efficacy of GGN. The aim of the present study was to evaluate the efficacy of GGN as a treatment for BPH. GGN administration was demonstrated to significantly decrease prostate weight (P<0.001), the relative prostate weight ratio (P<0.001) and the ratio of prostate weight to body weight (P<0.001). In addition, GGN treatment was revealed to suppress testosterone and dihydrotestosterone serum levels (P<0.001) and the growth of prostatic tissue. GGN also decreased the levels of the two inflammatory proteins (P<0.05), inducible nitric oxide synthase and cyclooxygenase-2, decreased the levels of the two apoptotic suppressors (P<0.05) B-cell lymphoma (Bcl)-2 and Bcl-xL and increased the levels of the pro-apoptotic factors (P<0.05) Bcl-2-associated X protein, caspase-3, caspase-8, Fas, Fas ligand and Fas-associated protein with death domain. The results of the present study suggested that GGN may have suppressive effects on the development of BPH and therefore have the potential to be used for treating BPH.

Entities:  

Keywords:  B-cell lymphoma 2; Ga-Gam-Nai-Go-Hyan; apoptosis; benign prostatic hyperplasia; inflammation

Year:  2017        PMID: 28450936      PMCID: PMC5403478          DOI: 10.3892/etm.2017.4088

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  36 in total

Review 1.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

Review 2.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

Review 3.  Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.

Authors:  Natasha Kyprianou
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

4.  Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Authors:  Franco Di Silverio; Cesare Bosman; Monti Salvatori; Luca Albanesi; Laura Proietti Pannunzi; Mauro Ciccariello; Antonio Cardi; Gianfilippo Salvatori; Alessandro Sciarra
Journal:  Eur Urol       Date:  2005-01       Impact factor: 20.096

Review 5.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

6.  Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats.

Authors:  Annamaria Morelli; Sandra Filippi; Paolo Comeglio; Erica Sarchielli; Aravinda K Chavalmane; Linda Vignozzi; Benedetta Fibbi; Enrico Silvestrini; Peter Sandner; Mauro Gacci; Marco Carini; Gabriella B Vannelli; Mario Maggi
Journal:  J Sex Med       Date:  2009-11-03       Impact factor: 3.802

7.  Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.

Authors:  Wanzhong Wang; Anders Bergh; Jan-Erik Damber
Journal:  Prostate       Date:  2004-09-15       Impact factor: 4.104

8.  Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Authors:  Grégoire Robert; Aurélien Descazeaud; Nathalie Nicolaïew; Stéphane Terry; Nanor Sirab; Francis Vacherot; Pascale Maillé; Yves Allory; Alexandre de la Taille
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

Review 9.  The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer.

Authors:  Johny E Elkahwaji
Journal:  Res Rep Urol       Date:  2012-12-31

10.  Foeniculum vulgare Mill. Protects against Lipopolysaccharide-induced Acute Lung Injury in Mice through ERK-dependent NF-κB Activation.

Authors:  Hui Su Lee; Purum Kang; Ka Young Kim; Geun Hee Seol
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

View more
  2 in total

Review 1.  The genus Cuscuta (Convolvolaceac): An updated review on indigenous uses, phytochemistry, and pharmacology.

Authors:  Shazia Noureen; Sobia Noreen; Shazia Akram Ghumman; Fozia Batool; Syed Nasir Abbas Bukhari
Journal:  Iran J Basic Med Sci       Date:  2019-11       Impact factor: 2.699

2.  Extracts of Phyllostachys pubescens Leaves Represses Human Steroid 5-Alpha Reductase Type 2 Promoter Activity in BHP-1 Cells and Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rat Model.

Authors:  Kwang Hoon Song; Chang-Seob Seo; Won-Kyung Yang; Hyun-O Gu; Ki-Joong Kim; Seung-Hyung Kim
Journal:  Nutrients       Date:  2021-03-09       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.